Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
My News Desk,
DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor in patients with and without type-2 diabetes Farxiga…